Schmidt, M
Supportivtherapie in der Gynäkologischen OnkologieGynäkologische Onkologie. Schattauer GmbH Verlag für Medizin und Naturwissenschaften 2017
Molokanova, O.; Schoenig, K.; Weng, S-Y et al.
Suppression of hepatic fibrosis by efficient Col1a1 silencing using shRNA inducible mouse modelsJOURNAL OF HEPATOLOGY. Bd. 66. H. 1. 2017 S. S653-S654
Prokosch-Willing, Verena; Vossmerbaeumer, Urs; Hoffmann, Esther et al.
Suprachoroidal Bleeding After XEN Gel ImplantationJOURNAL OF GLAUCOMA. Bd. 26. H. 12. 2017 S. E261-E263
Sagheb, Keyvan; Manz, Asina; Albrich, Stefan B. et al.
Supraclavicular Metastases from Distant Primary Solid Tumours: A Retrospective Study of 41 YearsJOURNAL OF MAXILLOFACIAL & ORAL SURGERY. Bd. 16. H. 2. 2017 S. 152-157
Bamberger, Denise; Hobernik, Dominika; Konhaeuser, Matthias et al.
Surface Modification of Polysaccharide-Based Nanoparticles with PEG and Dextran and the Effects on Immune Cell Binding and Stimulatory CharacteristicsMOLECULAR PHARMACEUTICS. Bd. 14. H. 12. 2017 S. 4403-4416
Staubitz, Julia Isabelle; Gassmann, Peter; Kauff, Daniel Wilhelm et al.
Surgical treatment strategies for giant inguinoscrotal hernia - a case report with review of the literatureBMC SURGERY. Bd. 17. 2017
Huber, T.; Kirschniak, A.; Johannink, J.
Survey of Training in Laparoscopic Skills in GermanyZENTRALBLATT FUR CHIRURGIE. Bd. 142. H. 1. 2017 S. 67-71
Barco, S.; Corti, M.; Trinchero, A. et al.
Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolismJOURNAL OF THROMBOSIS AND HAEMOSTASIS. Bd. 15. H. 7. 2017 S. 1436-1442
Schiegnitz, E.; Noelken, R.; Moergel, M. et al.
Survival and tissue maintenance of an implant with a sloped configurated shoulder in the posterior mandible-a prospective multicenter studyCLINICAL ORAL IMPLANTS RESEARCH. Bd. 28. H. 6. 2017 S. 721-726
Woerns, M. -A.; Merle, P.; Granito, A. et al.
Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placeboONCOLOGY RESEARCH AND TREATMENT. Bd. 40. 2017 S. 161-162